Page last updated: 2024-10-15

penciclovir

Description

penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135398748
CHEMBL ID1540
CHEBI ID7956
SCHEMBL ID3494
SCHEMBL ID19236307
MeSH IDM0151646

Synonyms (132)

Synonym
HMS3393D06
brl-39123
ccris 9213
penciclovir [usan:inn:ban]
penciclovirum [inn-latin]
9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine
D05407
denavir (tn)
penciclovir (usan/inn)
MLS001424110
penciclovir
C07417
39809-25-1
vectavir
PCV ,
denavir
adenovir
6h-purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)butyl)-
brl 39123
2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1h-purin-6-one
pencyclovir
mb2488
PE2 ,
9-(4-hydroxy-3-(hydroxymethyl)but-1-yl)guanine
MLS000759422
smr000466317
9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine
9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine
DB00299
9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine
9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine
NCGC00164630-01
HMS2090H11
HMS2051D06
nsc-759624
CHEMBL1540 ,
CHEBI:7956 ,
2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1,9-dihydro-6h-purin-6-one
penciclovirum
bdbm50210804
2-amino-9-(4-hydroxy-3-hydroxymethyl-butyl)-1,9-dihydro-purin-6-one(pcv, penciclovir)
2-amino-9-(4-hydroxy-3-hydroxymethyl-butyl)-1,9-dihydro-purin-6-one (pcv)
2-amino-9-(4-hydroxy-3-hydroxymethyl-butyl)-1,9-dihydro-purin-6-one
2-[2-(2-amino-6-hydroxy-purin-9-yl)-ethyl]-propane-1,3-diol
2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3h-purin-6-one
AKOS007930676
cas-39809-25-1
dtxsid9046491 ,
tox21_112248
dtxcid7026491
2-azanyl-9-[3-(hydroxymethyl)-4-oxidanyl-butyl]-3h-purin-6-one
A824740
pharmakon1600-01502320
nsc759624
HMS2232A11
S4184
CCG-101000
nsc 759624
hsdb 8123
unii-359hue8fjc
359hue8fjc ,
HY-17424
CS-1355
FT-0673555
FT-0601627
HMS3371P04
penciclovir [inn]
penciclovir [vandf]
penciclovir [mart.]
penciclovir [usan]
penciclovir [mi]
2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)butyl)-6h-purin-6-one
penciclovir [usp impurity]
penciclovir [orange book]
penciclovir [who-dd]
9-[4-hydroxy-3-(hydroxymethyl)butyl]guanine
CCG-213029
AB00698242-05
NC00250
SCHEMBL3494
tox21_112248_1
NCGC00263533-01
KS-5016
AB01275514-01
JNTOCHDNEULJHD-UHFFFAOYSA-N
6h-purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]-
penciceovir
P2164
AB01566918_01
AB01275514_02
2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6,9-dihydro-3h-purin-6-one
AKOS026750166
AC-8067
2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one
SR-01000763121-3
sr-01000763121
2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl)-1,9-dihydro-6h-purin-6-one
HMS3652H07
SR-05000001512-1
SR-05000001512-2
sr-05000001512
2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl)-3h-purin-6(9h)-one
mfcd00866931
NCGC00386270-02
HMS3713P14
SW197630-2
2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl)-1h-purin-6(9h)-one
SCHEMBL19236307
Q420364
2-[2-(2-amino-6-hydroxypurin-9-yl)ethyl]propane-1,3-diol
brl 39123;vsa 671
penciclovir,(s)
2-amino-9-(4-hydroxy-3-hydroxymethylbutyl)-1,9-dihydropurin-6-one
BCP13112
brl39123
EN300-1081992
2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6,9-dihydro-1h-purin-6-one
CCG-266987
2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3h-purin- 6-one
NCGC00263533-12
BP164247
penciclovir- bio-x
6h-purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl-3,3,4,4-d4]-
Z2025569265
j05ab13
2-amino-1,9-dihydro-9-
penciclovir (mart.)
penciclovir (usp impurity)
penciclovirum (inn-latin)
d06bb06
9-(2-hydroxy-1-(hydroxymethyl)-ethoxymethyl)guanine
penciclovirum (latin)

Research Excerpts

Overview

Penciclovir is a potent antiherpesvirus agent which is highly selective due to its phosphorylation only in virus infected cells. PenciclovIR is active against herpes simplex viruses located in the epidermis basal layer.

ExcerptReference
"Penciclovir is a selective inhibitor of EBV in cell culture."( Activity of penciclovir against Epstein-Barr virus.
Bacon, TH; Boyd, MR, 1995
)
"Penciclovir is a potent antiherpesvirus agent which is highly selective due to its phosphorylation only in virus infected cells. "( Use of isotopically chiral [4'-13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2 infected cells and by HSV-1-encoded thymidine kinase.
Darlison, SJ; Earnshaw, DL; Readshaw, SA; Vere Hodge, RA, 1993
)
"Penciclovir is a drug active against herpes simplex viruses located in the epidermis basal layer. "( Distribution to the skin of penciclovir after oral famciclovir administration in healthy volunteers: comparison of the suction blister technique and cutaneous microdialysis.
Benfeldt, E; Borg, N; Götharson, E; Groth, L; Ståhle, L, 1999
)

Effects

ExcerptReference
"Penciclovir-triphosphate has a prolonged in vitro intracellular half-life of 10 to 20 hours in HSV-1-and HSV-2-infected cells, respectively, and 9 to 14 hours in VZV-infected cells."( The pharmacological profile of famciclovir.
Crumpacker, C, 1996
)

Treatment

Treatment with penciclovir (intravenous formulation) was associated with the development of resistant HSV in only one severely immunocompromised patient. Treatment was effective and resulted in the complete clearance of the lesion by day 8.

ExcerptReference
"Penciclovir treatment for 12 or 24 weeks was not associated with any toxicity, establishing the efficacy and safety of long-term penciclovir therapy in chronic DHBV infection."( Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.
Colledge, D; Lin, E; Locarnini, S; Luscombe, C; Wang, YY, 1998
)
"Treatment with penciclovir (intravenous formulation) was associated with the development of resistant HSV in only one severely immunocompromised patient (day 7 isolate IC(50) = 2.01 microg/ml), although treatment was effective and resulted in the complete clearance of the lesion by day 8."( Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials.
Bacon, TH; Boon, RJ; Duffy, KE; Esser, KM; Leary, J; Locke, LA; Nguyen, TT; Quail, MR; Saltzman, R; Sarisky, RT, 2003
)

Toxicity

ExcerptReference
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
"3%) VZV-infected patients who received famciclovir three times a day experienced at least one adverse event."( Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Abrams, B; Arguedas, A; Bomgaars, L; De León Castrejón, T; Hamed, K; Kaiser, G; Looby, M; Roberts, M; Rodriguez, A; Sáez-Llorens, X; Spigarelli, MG; Yogev, R; Zhou, W, 2009
)
"Subconjunctival blank and penciclovir-impregnated implants were well tolerated at the ocular surface and not associated with systemic toxicity, adverse effect, or appreciable plasma penciclovir concentrations."( Pilot Study of the Safety and Tolerability of a Subconjunctival Penciclovir Implant in Cats Experimentally Infected with Herpesvirus.
Covert, JC; Kado-Fong, H; Kass, PH; Kon, LN; Lappin, MR; Maggs, DJ; Margulies, BJ; Reilly, CM; Thomasy, SM,
)

Pharmacokinetics

The pharmacokinetic profile of penciclovir was determined after a single 500-mg dose of its oral precursor, famcic Lovir, in 9 healthy volunteers and in 14 patients with chronic hepatic disease. Plasma and urine concentrations of penCiliclovir and its 6-deoxy precursor, BRL 42359, were determined and pencIClovir plasma concentration-time data submitted to model-independent pharmacodynamic analysis.

ExcerptReference
" Furthermore, there was no evidence that dose significantly affected any individual pharmacokinetic parameter."( The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects.
Fowles, SE; Pierce, DM; Prince, WT; Staniforth, D, 1992
)
"The pharmacokinetic profile of penciclovir was determined after a single 500-mg dose of its oral precursor, famciclovir, in 9 healthy volunteers and in 14 patients with chronic hepatic disease."( Pharmacokinetics of famciclovir in subjects with chronic hepatic disease.
Audet, PR; Boike, SC; Fairless, A; Freed, MI; Ilson, BE; Jorkasky, DK; Pue, M; Zariffa, N, 1994
)
" The possibility of a pharmacokinetic interaction between the anti-viral agent, famciclovir and allopurinol has been investigated in twelve healthy male volunteers following a single oral dose of famciclovir (500 mg) in the presence and absence of steady-state levels of allopurinol (300 mg)."( Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers.
Fowles, SE; Laroche, J; Pratt, SK; Prince, WT, 1994
)
" Plasma and urine concentrations of penciclovir and its 6-deoxy precursor, BRL 42359, were determined and penciclovir plasma concentration-time data submitted to model-independent pharmacokinetic analysis."( Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers.
Fairless, AJ; Fowles, S; Georgiou, P; Laroche, J; Pratt, SK; Prince, W; Pue, MA, 1994
)
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
" Pooled pharmacokinetic data were generated after single doses in 51 participants (approximately 12."( Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Abrams, B; Arguedas, A; Bomgaars, L; De León Castrejón, T; Hamed, K; Kaiser, G; Looby, M; Roberts, M; Rodriguez, A; Sáez-Llorens, X; Spigarelli, MG; Yogev, R; Zhou, W, 2009
)
" The concentrations of penciclovir declined in a biphasic manner after the peak concentration was attained."( Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses.
Kondo, T; Kurosawa, M; Matsumura, T; Nagata, S; Nemoto, M; Tsujimura, K; Yamada, M; Yamanaka, T, 2010
)
" Seventeen infants were included in the pharmacokinetic analysis; one infant experienced immediate emesis and was excluded."( Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children.
Blumer, J; Hamed, K; Kaiser, G; Rodriguez, A; Sallas, W; Sánchez, PJ, 2010
)
" The developed assay method was applied to a clinical pharmacokinetic study in human volunteers."( Determination of penciclovir in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study.
Bhatt, PA; Bhavesh, D; Kanneti, R; Paramar, D; Shivaprakash, R, 2011
)
"OBJECTIVES To determine, following oral administration of famciclovir, pharmacokinetic (PK) parameters for 2 of its metabolites (penciclovir and BRL42359) in plasma and tears of healthy cats so that famciclovir dosage recommendations for the treatment of herpetic disease can be optimized."( Pharmacokinetic modeling of penciclovir and BRL42359 in the plasma and tears of healthy cats to optimize dosage recommendations for oral administration of famciclovir.
Knych, HK; Maggs, DJ; Sebbag, L; Thomasy, SM; Woodward, AP, 2016
)

Compound-Compound Interactions

ExcerptReference
" 3TC and PCV are deoxycytidine and deoxyguanosine analogs, respectively, and their modes of action and how they interact are matters of both theoretical and practical interest."( Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro.
Colledge, D; Locarnini, S; Shaw, T, 1997
)
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)

Bioavailability

A series of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines (4-10) were evaluated for their oral penciclovir bioavailability in mice and rats. The amino acid ester derivatives of 6-deoxypencic Lovir, 11-20, were synthesized as potential prodrugs. These data indicate that introduction of an isopropoxy carbonate could improve the efficacy and bioavailability of pencIClovir.

ExcerptReference
"Potential oral prodrugs of the antiherpesvirus acyclonucleoside 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (1, BRL 39123) have been synthesized and evaluated for bioavailability of 1 in the blood of mice."( Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties.
Boyd, MR; Harnden, MR; Jarvest, RL; Sutton, D; Vere Hodge, RA, 1989
)
" PCV and ACV reduced virus replication to a similar extent when given ad libitum in drinking water, even though ACV had better oral bioavailability and greater potency in murine cells."( Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16.
Boyd, MR; Sutton, D, 1993
)
"Famciclovir is the well-absorbed oral form of penciclovir, a potent and selective antiviral agent, with activity against members of the herpesvirus family, including varicella-zoster virus (VZV), and herpes simplex virus-1 (HSV-1) and HSV-2."( The pharmacological profile of famciclovir.
Crumpacker, C, 1996
)
" Much of the current antiviral research focuses on providing drugs with (i) improved oral bioavailability and pharmacokinetics which permit less frequent oral or topical dosing for suppressive treatment of herpes simplex virus (HSV) infections, (ii) different mechanisms of action for synergic effects in treating resistant HSV infections in the immunocompromised host and (iii) improved efficacy."( New therapeutic approaches to the alphaherpesvirus infections.
Cassady, KA; Whitley, RJ, 1997
)
"A series of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines (4-10) and 2-amino-9-(2-(2-oxo-1,3-dioxan-5-yl)ethyl)purine (1) were synthesized as potential prodrugs of penciclovir and evaluated for their oral penciclovir bioavailability in mice and rats."( Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir.
Chang, K; Cho, YB; Choi, WS; Hwang, YY; Im, GJ; Jung, I; Kim, DK; Kim, JS; Kim, KH; Kim, TS; Kim, YW; Lee, N; Min, DS; Um, KA, 1998
)
"The amino acid ester derivatives of 6-deoxypenciclovir, 11-20, were synthesized as potential prodrugs of penciclovir, and were evaluated for their oral penciclovir bioavailability in mice and rats."( Synthesis and evaluation of amino acid esters of 6-deoxypenciclovir as potential prodrugs of penciclovir.
Chang, K; Choi, WS; Im, GJ; Kim, DK; Kim, KH; Kim, YW; Lee, N, 1999
)
" It showed good oral bioavailability in rats (68."( Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.
Aoki, M; Iwayama, S; Mukai, C; Nakagawa, R; Nakazawa, H; Ohmura, Y; Okunishi, M; Onishi, T; Ono, N; Sekiyama, T; Suzuki, K; Tsuji, T, 2000
)
" These data indicate that introduction of an isopropoxy carbonate group into one of the two hydroxyl groups of M4 did not significantly alter the oral bioavailability of penciclovir compared with famciclovir."( Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir.
Chang, K; Choi, WS; Im, GJ; Jung, I; Kim, DK; Kim, JS; Kim, TK; Kim, TS; Kim, YW; Lee, N; Lee, SJ, 2001
)
"Hydrophilic drugs are poorly absorbed when applied topically, due to low partitioning through the lipid matrix of the stratum corneum."( The role of stratum corneum and dermal microvascular perfusion in penetration and tissue levels of water-soluble drugs investigated by microdialysis.
Friedmann, PS; Morgan, CJ; Renwick, AG, 2003
)
"tert-Azido or amino substituted penciclovir analogs, 1-3 were synthesized for the purpose of improving the efficacy and bioavailability of penciclovir and searching for novel antiviral agents."( Synthesis and biological evaluation of novel tert-azido or tert-amino substituted penciclovir analogs.
Baek, HW; Chun, MW; Jeong, LS; Kim, DK; Kim, HO; Moon, HR, 2004
)
" Subsequently, the orally bioavailable prodrugs valaciclovir and famciclovir have been introduced."( Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug.
Beutner, K; Chakrabarty, A; Rauser, M; Tyring, SK, 2004
)
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
"4 hours, respectively; and penciclovir bioavailability was 12."( Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir.
Bales, JL; Ferrone, M; Maggs, DJ; Stanley, SD; Thomasy, SM; Whittem, T, 2012
)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
" Obtained results show that tested modification do not improve bioavailability of nucleoside analogs in cells."( Modifications on the heterocyclic base of ganciclovir, penciclovir, acyclovir - syntheses and antiviral properties.
Chayrov, R; Chuchkov, K; Hinkov, A; Shishkova, K; Stankova, IG; Todorov, D, 2020
)
" Compared to a marketed 1% PV cream, the O3 formulation exhibited a significantly higher and sustained PV release, nearly twice the PV permeability, and a relative bioavailability of 180%."( Oral gel loaded with penciclovir-lavender oil nanoemulsion to enhance bioavailability and alleviate pain associated with herpes labialis.
Abdulaal, WH; Abualsunun, WA; Alghaith, AF; Alhakamy, NA; Ali, SA; Alkhalidi, HM; Alruwaili, NK; Alshehri, S; Alsuabeyl, MS; Bahmdan, RH; Bakhaidar, RB; Hosny, KM; Kurakula, M; Nassar, MS; Rizg, WY; Sindi, AM, 2021
)

Dosage Studied

Famciclovir pharmacokinetics following oral famcic Lovir administration in cats appeared complex within the dosage range studied. Dosage adjustment is not required for famciellir in elderly patients with normal or mildly impaired renal function, and the extent of pencivelovir availability is not affected by food.

ExcerptReference
" These subsequent studies confirmed that, after oral dosing with famciclovir, more than half the dose was absorbed and rapidly converted to penciclovir."( Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir].
Boyd, MR; Harnden, MR; Jarvest, RL; Sutton, D; Vere Hodge, RA, 1989
)
" Both 5 and its esters (14-17, 21, 22) and also 18 were well absorbed after oral administration and converted efficiently to 1, the diacetyl (14) and dipropionyl (16) esters providing concentrations of 1 in the blood that were more than 15-fold higher than those observed after dosing either 1 or its esters (25-27)."( Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties.
Boyd, MR; Harnden, MR; Jarvest, RL; Sutton, D; Vere Hodge, RA, 1989
)
" On oral dosing of famciclovir to humans, only penciclovir and BRL 42359 can be detected consistently in the plasma; thus, attention was focused on the oxidation reaction."( Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.
Chenery, RJ; Clarke, SE; Harrell, AW, 1995
)
" This new drug produces enhanced plasma levels of acyclovir following oral dosing, which will not only allow more convenient dosing for the treatment of herpes simplex virus and varicella zoster virus (VZV) infections, but also mean that valaciclovir has the potential for superior clinical efficacy over acyclovir."( Acyclovir--and beyond.
Darby, G, 1994
)
" Dosage adjustment is required in the presence of renal impairment."( Pharmacokinetics of new antiherpetic agents.
Rolan, P, 1995
)
" The dose-response curve for GCV appeared more exponential, without a threshold, but with a no-effect dose of around 150 mumols/kg per day."( Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay.
Haynes, P; Lambert, TR; Mitchell, ID, 1996
)
" Dosage adjustment is not required for famciclovir in elderly patients with normal or mildly impaired renal function, and the extent of penciclovir availability is not affected by food."( The pharmacological profile of famciclovir.
Crumpacker, C, 1996
)
" Much of the current antiviral research focuses on providing drugs with (i) improved oral bioavailability and pharmacokinetics which permit less frequent oral or topical dosing for suppressive treatment of herpes simplex virus (HSV) infections, (ii) different mechanisms of action for synergic effects in treating resistant HSV infections in the immunocompromised host and (iii) improved efficacy."( New therapeutic approaches to the alphaherpesvirus infections.
Cassady, KA; Whitley, RJ, 1997
)
"Ducks congenitally infected with duck hepatitis B virus (DHBV) were treated with the antiviral guanine nucleoside analog penciclovir for 12 or 24 weeks at a dosage of 10 mg/kg of body weight per day."( Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.
Colledge, D; Lin, E; Locarnini, S; Luscombe, C; Wang, YY, 1998
)
" In conclusion, PCV q12h is a well-tolerated and effective therapy for mucocutaneous HSV infection in IC patients and offers a reduced frequency of dosing compared with ACV q8h."( Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group.
Aoun, M; Belanger, R; Candoni, A; Jurewicz, R; Lazarus, HM; Marks, L, 1999
)
" The values of C(max), AUC, and urinary recovery of penciclovir after dosing with SK1899 to rats and dogs were similar or slightly higher than those from famciclovir."( Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir.
Chang, K; Choi, WS; Im, GJ; Jung, I; Kim, DK; Kim, JS; Kim, TK; Kim, TS; Kim, YW; Lee, N; Lee, SJ, 2001
)
" These compounds offer high oral bioavailabilty and deliver acyclovir and penciclovir, respectively, to the target cells by means of more convenient dosing schedules."( Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug.
Beutner, K; Chakrabarty, A; Rauser, M; Tyring, SK, 2004
)
"Penciclovir pharmacokinetics following oral famciclovir administration in cats appeared complex within the dosage range studied."( Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats.
Maggs, DJ; Moulin, NK; Stanley, SD; Thomasy, SM, 2007
)
" An eight-step weight-based dosing regimen was developed to optimize exposure in smaller children and was used in the 7-day multiple-dose safety phases of both studies, which enrolled 100 patients with confirmed/suspected viral infections."( Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Abrams, B; Arguedas, A; Bomgaars, L; De León Castrejón, T; Hamed, K; Kaiser, G; Looby, M; Roberts, M; Rodriguez, A; Sáez-Llorens, X; Spigarelli, MG; Yogev, R; Zhou, W, 2009
)
" An eight-step dosing regimen was derived that targeted exposure in infants and children 6 months to 12 years of age to match the penciclovir AUC seen in adults after a 500-mg dose of famciclovir."( Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children.
Blumer, J; Hamed, K; Kaiser, G; Rodriguez, A; Sallas, W; Sánchez, PJ, 2010
)
"Penciclovir pharmacokinetics following oral administration of famciclovir were nonlinear within the dosage range studied, likely because of saturation of famciclovir metabolism."( Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir.
Bales, JL; Ferrone, M; Maggs, DJ; Stanley, SD; Thomasy, SM; Whittem, T, 2012
)
"OBJECTIVES To determine, following oral administration of famciclovir, pharmacokinetic (PK) parameters for 2 of its metabolites (penciclovir and BRL42359) in plasma and tears of healthy cats so that famciclovir dosage recommendations for the treatment of herpetic disease can be optimized."( Pharmacokinetic modeling of penciclovir and BRL42359 in the plasma and tears of healthy cats to optimize dosage recommendations for oral administration of famciclovir.
Knych, HK; Maggs, DJ; Sebbag, L; Thomasy, SM; Woodward, AP, 2016
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2-aminopurinesAny aminopurine having the amino substituent at the 2-position.
propane-1,3-diolsAny propanediol bearing hydroxy groups at positions 1 and 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.07500.006038.004119,952.5996AID1159521
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
TDP1 proteinHomo sapiens (human)Potency1.17360.000811.382244.6684AID686978; AID686979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinase Macacine alphaherpesvirus 1IC50 (µMol)84.40000.15002.57504.2000AID326127
Thymidine kinaseHuman alphaherpesvirus 1 (Herpes simplex virus type 1)IC50 (µMol)11.00000.15004.81679.0000AID280124
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POU domain, class 2, transcription factor 2Homo sapiens (human)Km284.00002.70002.70002.7000AID1219943
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
humoral immune responsePOU domain, class 2, transcription factor 2Homo sapiens (human)
positive regulation of interleukin-6 productionPOU domain, class 2, transcription factor 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 2Homo sapiens (human)
cellular response to virusPOU domain, class 2, transcription factor 2Homo sapiens (human)
regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPOU domain, class 2, transcription factor 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 2Homo sapiens (human)
DNA-binding transcription factor activityPOU domain, class 2, transcription factor 2Homo sapiens (human)
sequence-specific DNA bindingPOU domain, class 2, transcription factor 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingPOU domain, class 2, transcription factor 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPOU domain, class 2, transcription factor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleusPOU domain, class 2, transcription factor 2Homo sapiens (human)
nucleoplasmPOU domain, class 2, transcription factor 2Homo sapiens (human)
cytoplasmPOU domain, class 2, transcription factor 2Homo sapiens (human)
intracellular membrane-bounded organellePOU domain, class 2, transcription factor 2Homo sapiens (human)
chromatinPOU domain, class 2, transcription factor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (281)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID723372Antiviral activity against Varicella zoster virus Ellen infected in human MRC5 cells assessed as inhibition of viral replication by viral reduction plaque assay2013Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2
Antiviral activity of (+)-sattabacin against varicella zoster.
AID106198compound was tested for antiviral activity against Herpes Simplex virus Type-2(21929) in human lung fibroblasts (MRC-5)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.
AID555162Toxicity in VZV-infected 1 to <2 years aged pediatric patient assessed as incidence of abdominal pain at 40.8 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1219939Drug transport in human OCT2 expressed in HEK Flp-In cells at 0.07 uM for 10 mins relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID1572743Cytostatic activity against human K562 cells2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID554883Tmax in 6 to <=12 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1572737Cytostatic activity against human hTERT-RPE1 cells2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID554893AUC (0 to infinity) in 1 to <2 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID216040Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells.1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1451459Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID554924Toxicity in orally dosed HSV-infected patient assessed as incidence of nausea administered as bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID106003Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells.1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID554902Apparent oral clearance in 2 to <6 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1219941Drug transport in human ENT in HEK cells in presence of 100 uM ENT inhibitor benzythioinosine2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID554890AUC (0 to last) in 2 to <6 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID555168Toxicity in VZV-infected 6 to <=12 years aged pediatric patient assessed as incidence of nausea at 35.5 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1219942Drug transport in human OAT2 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID555151Toxicity in VZV-infected 2 to <6 years aged pediatric patient assessed as incidence of diarrhea at 40.6 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1219943Drug transport in human OAT2 expressed in HEK Flp-In cells2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID555143Toxicity in HSV-infected 2 to <6 years aged pediatric patient assessed as pyrexia at 27.6 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID554921Toxicity in HSV-infected 1 to <2 years aged pediatric patient assessed as incidence of nausea at 30.9 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1451454Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID555172Toxicity in VZV-infected 6 to <=12 years aged pediatric patient assessed as incidence of cellulitis at 35.5 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID554915Toxicity in HSV-infected 6 to <=12 years aged pediatric patient assessed as incidence of diarrhea at 23.5 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1717750Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for 2019-nCoV Beta CoV/Wuhan/WIV04/2019 infected in African green monkey Vero E6 cells2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID554882Tmax in 2 to <6 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555171Toxicity in VZV-infected 2 to <6 years aged pediatric patient assessed as incidence of cellulitis at 40.6 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1857469Oral bioavailability in human at 400 mg administered as 1 hr intravenous infusion2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections.
AID81018Tested for Antiherpetic activity against VZV from Kawaguchi strain in HEL cell lines.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.
AID1451455Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID580184Cytotoxicity against human HepG2(2.2.15) cells by neutral red dye uptake assay2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV).
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID109694Concentration of 9-[4-Hydroxy-3-(hydroxymethyl)but-1-yl)guanine in blood of mice after 3 hours upon oral administration1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties.
AID555175Toxicity in VZV-infected 2 to <6 years aged pediatric patient assessed as incidence of headache at 40.6 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID106194compound was tested for antiviral activity against Herpes Simplex virus Type-1(20132) in human lung fibroblasts (MRC-5)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.
AID554908Toxicity in orally dosed HSV-infected patient assessed as at least one adverse event administered as bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID106197compound was tested for antiviral activity against Herpes Simplex virus Type-2(20605) in human lung fibroblasts (MRC-5)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.
AID1692501Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
COVID-19: Drug Targets and Potential Treatments.
AID87640Antiviral activity against HSV-1 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures)1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.
AID53487Inhibition of DNA polymerase1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.
AID86827Percentage of diphosphates (DP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.
AID217723Compound was tested for antiviral activity against Herpes Simplex virus Type-2(MS) in vero cells1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.
AID1410511Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Amidate Prodrugs of Cyclic 9-(
AID1572729Antiviral activity against herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID554927Toxicity in HSV-infected 6 to <=12 years aged pediatric patient assessed as incidence of cough at 23.5 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID554894AUC (0 to infinity) in 2 to <6 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1451452Antiviral activity against human cytomegalovirus AD-169 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID53759In vitro antiviral activity against duck hepatitis B virus (DHBV)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Synthesis and antiviral activity of novel acyclic nucleoside analogues of 5-(1-azido-2-haloethyl)uracils.
AID63719Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls.2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID109691Concentration of 9-[4-Hydroxy-3-(hydroxymethyl)but-1-yl)guanine in blood of mice after 0.25 hours upon oral administration1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties.
AID1451460Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID554917Toxicity in HSV-infected 1 to <2 years aged pediatric patient assessed as incidence of headache at 30.9 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555153Toxicity in orally dosed VZV-infected patient assessed as incidence of diarrhea administered as tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID554930Toxicity in HSV-infected 2 to <6 years aged pediatric patient assessed as incidence of abdominal pain at 27.6 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1572731Antiviral activity against thymidine kinase deficient and aciclovir resistant herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID53466Inhibition of DNA polymerase1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.
AID392509Antiviral activity against Hepatitis B virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1572741Cytostatic activity against human DND41 cells2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID45815The mitochondrial toxicity was measured on human T-lymphoid CEM cells.2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID217495The effective concentration to show 50% of activity was measured on varicella zoster virus(VZV) cell culture2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID1219944Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT2 expressed in HEK Flp-In cells measured per mg of protein2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID106007Tested for Antiherpetic activity against HSV-1 from Tomioka strain in MRC-5 cell lines.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID554887Cmax in 6 to <=12 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID326135Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID28660Aqueous solubility at 25 degrees Centigrade1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties.
AID555169Toxicity in orally dosed VZV-infected patient assessed as incidence of nausea administered as tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1410503Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Amidate Prodrugs of Cyclic 9-(
AID555174Toxicity in VZV-infected 1 to <2 years aged pediatric patient assessed as incidence of headache at 40.8 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1451461Cytotoxicity against human HEL cells assessed as alteration to cell morphology by microscopic analysis2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID218501Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay; ND means Not determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity.
AID53756Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures.2002Journal of medicinal chemistry, May-09, Volume: 45, Issue:10
Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus.
AID554909Toxicity in HSV-infected 1 to <2 years aged pediatric patient assessed as incidence of vomiting at 30.9 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID82116Antiviral activity against HIV-1 was determined; No inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation.
AID555144Toxicity in HSV-infected 6 to <=12 years aged pediatric patient assessed as pyrexia at 23.5 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID87443Percentage of triphosphates (TP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.
AID554881Tmax in 1 to <2 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555164Toxicity in VZV-infected 6 to <=12 years aged pediatric patient assessed as incidence of abdominal pain at 35.5 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555149Toxicity in orally dosed VZV-infected patient assessed as at least one adverse event administered as tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID554911Toxicity in HSV-infected 6 to <=12 years aged pediatric patient assessed as incidence of vomiting at 23.5 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1451453Antiviral activity against HIV1 X4LAI.04 infected in human MT4 cells assessed as decrease in viral replication by p24gag-based luminex assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID555180Toxicity in VZV-infected 6 to <=12 years aged pediatric patient assessed as incidence of pruritus at 35.5 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID85890Compound was tested for in vitro antiviral activity against herpes viruses of type 1 (HSV-1,KOS strain) (concentration required to reduce the OD value by 50% of the virus infected control)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID555141Toxicity in orally dosed HSV-infected patient assessed as incidence of abdominal pain administered as bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555140Toxicity in HSV-infected 6 to <=12 years aged pediatric patient assessed as incidence of abdominal pain at 23.5 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555177Toxicity in orally dosed VZV-infected patient assessed as incidence of headache administered as tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID326136Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID555148Toxicity in VZV-infected 6 to <=12 years aged pediatric patient assessed as at least one adverse event at 35.5 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID554926Toxicity in HSV-infected 2 to <6 years aged pediatric patient assessed as incidence of cough at 27.6 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID554897Half life in 1 to <2 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555158Toxicity in VZV-infected 1 to <2 years aged pediatric patient assessed as pyrexia at 40.8 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID554929Toxicity in HSV-infected 1 to <2 years aged pediatric patient assessed as incidence of abdominal pain at 30.9 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID106192compound was tested for antiviral activity against Herpes Simplex virus Type-1(18189) in human lung fibroblasts (MRC-5)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.
AID280123Inhibition of recombinant VZV TK assessed as [CH3-H3]dThd phosphorylation2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Synthesis and preliminary evaluation of 18F- or 11C-labeled bicyclic nucleoside analogues as potential probes for imaging varicella-zoster virus thymidine kinase gene expression using positron emission tomography.
AID106193compound was tested for antiviral activity against Herpes Simplex virus Type-1(19407) in human lung fibroblasts (MRC-5)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID555152Toxicity in VZV-infected 6 to <=12 years aged pediatric patient assessed as incidence of diarrhea at 35.5 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1572734Antiviral activity against thymidine kinase deficient Varicella-zoster virus 07-1 infected in HEL cells assessed as reduction in virus plaque formation2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID555173Toxicity in orally dosed VZV-infected patient assessed as incidence of cellulitis administered as tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1410504Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Amidate Prodrugs of Cyclic 9-(
AID1451462Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID87303Percentage of monophosphates (MP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.
AID326131Activity of Herpes B virus recombinant thymidine kinase at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID66959The effective concentration to show 50% of activity was measured on Epstein Barr virus(EBV) cell culture; ND means not determined.2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID554916Toxicity in orally dosed HSV-infected patient assessed as incidence of diarrhea administered as bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID209950Concentration required to reduce the proliferation of PHA stimulated human peripheral blood T lymphocytes; ND means Not determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity.
AID14359The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir.
AID218507Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells; ND means Not determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity.
AID14358The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID326138Cytotoxicity against african green monkey Vero cells after 2 days2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID555159Toxicity in VZV-infected 2 to <6 years aged pediatric patient assessed as pyrexia at 40.6 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID580183Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV).
AID555176Toxicity in VZV-infected 6 to <=12 years aged pediatric patient assessed as incidence of headache at 35.5 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID326137Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID216038Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells.1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides.
AID1572735Antiviral activity against Human cytomegalovirus AD169 assessed as reduction in virus-induced cytopathogenicity by microscopic analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1451465Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID1692496Antiviral activity against nCoV-2019 BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells assessed as reduction in viral yield preincubated for 1 hr followed by viral infection and further replacement of fresh medium containing compound 2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
COVID-19: Drug Targets and Potential Treatments.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID554906Toxicity in HSV-infected 2 to <6 years aged pediatric patient assessed as at least one adverse event at 27.6 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1410509Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Amidate Prodrugs of Cyclic 9-(
AID1451457Antiviral activity against HIV1 X4LAI.04 infected in human tonsillar tissues assessed as inhibition of virus-induced cytopathic effect by p24gag-based luminex assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID1219937Drug transport in human OAT1 expressed in HEK Flp-In cells at 0.07 uM for 10 mins relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID45814Dose that inhibited 50% cell growth of human T-lymphoid CEM cells compared with untreated control2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID84224The effective concentration to show 50% of activity was measured on herpes simplex virus-1 with strain KOS cell culture.2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID280124Inhibition of recombinant HSV-1 TK assessed as [CH3-H3]dThd phosphorylation2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Synthesis and preliminary evaluation of 18F- or 11C-labeled bicyclic nucleoside analogues as potential probes for imaging varicella-zoster virus thymidine kinase gene expression using positron emission tomography.
AID554898Half life in 2 to <6 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1717749Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1410506Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka assessed as inhibition of plaque formation measured after 5 days post-infection2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Amidate Prodrugs of Cyclic 9-(
AID554918Toxicity in HSV-infected 2 to <6 years aged pediatric patient assessed as incidence of headache at 27.6 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1410507Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 assessed as inhibition of plaque formation measured after 5 days post-infection2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Amidate Prodrugs of Cyclic 9-(
AID1572744Cytostatic activity against human Z138 cells2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID554885Cmax in 1 to <2 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1572736Antiviral activity against Human cytomegalovirus Davis assessed as reduction in virus-induced cytopathogenicity by microscopic analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID555178Toxicity in VZV-infected 1 to <2 years aged pediatric patient assessed as incidence of pruritus at 40.8 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID326127Inhibition of Herpes B virus recombinant thymidine kinase-mediated [3H]TdR phosphorylation2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID106195compound was tested for antiviral activity against Herpes Simplex virus Type-1(HFEM) in human lung fibroblasts (MRC-5)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1219938Drug transport in human OAT3 expressed in HEK Flp-In cells at 0.07 uM for 10 mins relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1572730Antiviral activity against herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1219931Drug transport in human OAT2 expressed in HEK Flp-In cells at 0.07 uM for 10 mins relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID554920Toxicity in orally dosed HSV-infected patient assessed as incidence of headache administered as bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID280163Cytostatic activity against OST TK-/HSV1 TK+ cells at 0.038 uM2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Synthesis and preliminary evaluation of 18F- or 11C-labeled bicyclic nucleoside analogues as potential probes for imaging varicella-zoster virus thymidine kinase gene expression using positron emission tomography.
AID1572732Cytotoxicity against HEL cells assessed as effect on cell morphology at 0.32 to 200 uM by microscopic analysis2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID555161Toxicity in orally dosed VZV-infected patient assessed as pyrexia administered as tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1410505Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Amidate Prodrugs of Cyclic 9-(
AID554913Toxicity in HSV-infected 1 to <2 years aged pediatric patient assessed as incidence of diarrhea at 30.9 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1572740Cytostatic activity against human NCI-H460 cells2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1410508Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Amidate Prodrugs of Cyclic 9-(
AID554922Toxicity in HSV-infected 2 to <6 years aged pediatric patient assessed as incidence of nausea at 27.6 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID106199compound was tested for antiviral activity against Herpes Simplex virus Type-2(MS) in human lung fibroblasts (MRC-5)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.
AID1451463Antiviral activity against Varicella-Zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID554901Apparent oral clearance in 1 to <2 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID555150Toxicity in VZV-infected 1 to <2 years aged pediatric patient assessed as incidence of diarrhea at 40.8 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID326134Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID554914Toxicity in HSV-infected 2 to <6 years aged pediatric patient assessed as incidence of diarrhea at 27.6 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555167Toxicity in VZV-infected 2 to <6 years aged pediatric patient assessed as incidence of nausea at 40.6 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID87302Percentage of monophosphates (MP) formed in the first step of staggered assay compound was incubated with HSV-1 thymidine kinase for 4 hr1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.
AID554886Cmax in 2 to <6 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555157Toxicity in orally dosed VZV-infected patient assessed as incidence of vomiting administered as tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1572742Cytostatic activity against human HL60 cells2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID554923Toxicity in HSV-infected 6 to <=12 years aged pediatric patient assessed as incidence of nausea at 23.5 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID217722Compound was tested for antiviral activity against Herpes Simplex virus Type-1(HFEM) in vero cells1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.
AID554912Toxicity in orally dosed HSV-infected patient assessed as incidence of vomiting administered as bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID554925Toxicity in HSV-infected 1 to <2 years aged pediatric patient assessed as incidence of cough at 30.9 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID85278The effective concentration to show 50% of activity was measured on Herpes simplex virus type-2 with strain 300 cell culture;ND means no data2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID1410510Cytotoxicity against HEL cells assessed as morphological changes after 3 days by microscopic analysis2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Amidate Prodrugs of Cyclic 9-(
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID106196compound was tested for antiviral activity against Herpes Simplex virus Type-2(17409) in human lung fibroblasts (MRC-5)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.
AID555165Toxicity in orally dosed VZV-infected patient assessed as incidence of abdominal pain administered as tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID90940Antiviral activity against HCMV was determined; No inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation.
AID555146Toxicity in VZV-infected 1 to <2 years aged pediatric patient assessed as at least one adverse event at 40.8 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID106008Tested for Antiherpetic activity against HSV-2 from 186 strain in MRC-5 cell lines.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.
AID554910Toxicity in HSV-infected 2 to <6 years aged pediatric patient assessed as incidence of vomiting at 27.6 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID218505Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells; ND means Not determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity.
AID1572739Cytostatic activity against human HAP1 cells2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID87834Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures)1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID554889AUC (0 to last) in 1 to <2 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555179Toxicity in VZV-infected 2 to <6 years aged pediatric patient assessed as incidence of pruritus at 40.6 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID106002Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells.1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides.
AID1572738Cytostatic activity against human Capan1 cells2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID109692Concentration of 9-[4-Hydroxy-3-(hydroxymethyl)but-1-yl)guanine in blood of mice after 1 hour upon oral administration1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties.
AID554903Apparent oral clearance in 6 to <=12 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555142Toxicity in HSV-infected 1 to <2 years aged pediatric patient assessed as pyrexia at 30.9 mg/kg, po administered as bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555163Toxicity in VZV-infected 2 to <6 years aged pediatric patient assessed as incidence of abdominal pain at 40.6 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID554895AUC (0 to infinity) in 6 to <=12 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID555166Toxicity in VZV-infected 1 to <2 years aged pediatric patient assessed as incidence of nausea at 40.8 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555154Toxicity in VZV-infected 1 to <2 years aged pediatric patient assessed as incidence of vomiting at 40.8 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555156Toxicity in VZV-infected 6 to <=12 years aged pediatric patient assessed as incidence of vomiting at 35.5 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID554891AUC (0 to last) in 6 to <=12 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555147Toxicity in VZV-infected 2 to <6 years aged pediatric patient assessed as at least one adverse event at 40.6 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID217408Compound was tested for cytotoxicity in Vero cells (concentration required to reduce the OD value by 50% of the control)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID554907Toxicity in HSV-infected 6 to <=12 years aged pediatric patient assessed as at least one adverse event at 23.5 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID554919Toxicity in HSV-infected 6 to <=12 years aged pediatric patient assessed as incidence of headache at 23.5 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555160Toxicity in VZV-infected 6 to <=12 years aged pediatric patient assessed as pyrexia at 35.5 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID63718Percent inhibition of viral DNA in the presence of 10 mg/mL compound compared to untreated infected controls in duck hepatocytes; ND means Not determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity.
AID555145Toxicity in orally dosed HSV-infected patient assessed as pyrexia administered as bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1525703Oral bioavailability in human2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID554899Half life in 6 to <=12 years aged pediatric patient administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555155Toxicity in VZV-infected 2 to <6 years aged pediatric patient assessed as incidence of vomiting at 40.6 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555181Toxicity in orally dosed VZV-infected patient assessed as incidence of pruritus administered as tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1451458Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID81019Tested for Antiherpetic activity against VZV from clinical isolates of HEL cell lines.(average of 11 isolates)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.
AID1572733Antiviral activity against Varicella-zoster virus Oka harboring thymidine kinase infected in HEL cells assessed as reduction in virus plaque formation2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID554905Toxicity in HSV-infected 1 to <2 years aged pediatric patient assessed as at least one adverse event at 30.9 mg/kg, po bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID555170Toxicity in VZV-infected 1 to <2 years aged pediatric patient assessed as incidence of cellulitis at 40.8 mg/kg, po tid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID1451464Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
AID554928Toxicity in orally dosed HSV-infected patient assessed as incidence of cough administered as bid2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1717748Antiviral activity against 2019-nCoV BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells assessed as reduction in viral yield preincubated with virus for 1 hr followed by cell infection and measured after 2 hrs by qRT-PCR method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (248)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (3.63)18.7374
1990's72 (29.03)18.2507
2000's99 (39.92)29.6817
2010's47 (18.95)24.3611
2020's21 (8.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials21 (8.05%)5.53%
Reviews35 (13.41%)6.00%
Case Studies2 (0.77%)4.05%
Observational0 (0.00%)0.25%
Other203 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind, to Compare Non-inferiority Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis.[NCT01257074]Phase 376 participants (Actual)Interventional2012-02-29Completed
A Randomised, Double-blind, Vehicle Controlled, Single Center, Parallel Group, Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers[NCT00820534]Phase 4126 participants (Actual)Interventional2008-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00820534 (2) [back to overview]Clinical Assessment Performed by the Investigator and Skin Temperature at the Cold Sore.
NCT00820534 (2) [back to overview]Size of the Cold Sore

Clinical Assessment Performed by the Investigator and Skin Temperature at the Cold Sore.

Number of participants where the classical cold sore lesion was prevented at 72 hours after first treatment application.Lesion defined as having been prevented if clinical assessment is prodrome, macule or healed and skin temperature of the cold sore is negative (temperature difference of less than 0.5°C between initial site of cold sore and opposite side). (NCT00820534)
Timeframe: 72 hours

Interventionparticipants (Number)
Penciclovir39
Placebo32

[back to top]

Size of the Cold Sore

The size of the cold sore was measured as follows : a standardized photograph was taken before treatment and compared to a photograph taken 72 hours after the first treatment application. The difference was calculated for each participant within each treatment arm. (NCT00820534)
Timeframe: 72 hours

Interventionsquare mm (Mean)
Penciclovir31.7
Placebo32.7

[back to top]